ARTICLES BY STANTON R. MEHR
-
![Cards]( "Which Biosimilar Companies Will Thrive In 2025?")
Which Biosimilar Companies Will Thrive In 2025?3/31/2020Five years after the first biosimilar was made available for prescription in the U.S., the American biosimilar market may be turning a corner on the road to sustainability.
Stanton R. Mehr
Stanton Mehr is content director of Biosimilars Review & Report (www.biosimilarsrr.com) and president of SM Health Communications (www.smhealthcom.com). He consults on payer issues and health policy, as well as on the biosimilar arena. Email address: stan.mehr@smhealthcom.com.
This website uses cookies to ensure you get the best experience on our website. Learn more